coin-img-ETHETH+1.01%coin-img-BTCBTC+1.00%coin-img-SOLSOL+1.21%coin-img-USDCUSDC+0.01%coin-img-XRPXRP-0.68%coin-img-TRXTRX-0.54%coin-img-BNBBNB+1.72%coin-img-HYPEHYPE+5.22%coin-img-ETHETH+1.01%coin-img-BTCBTC+1.00%coin-img-SOLSOL+1.21%coin-img-USDCUSDC+0.01%coin-img-XRPXRP-0.68%coin-img-TRXTRX-0.54%coin-img-BNBBNB+1.72%coin-img-HYPEHYPE+5.22%coin-img-ETHETH+1.01%coin-img-BTCBTC+1.00%coin-img-SOLSOL+1.21%coin-img-USDCUSDC+0.01%coin-img-XRPXRP-0.68%coin-img-TRXTRX-0.54%coin-img-BNBBNB+1.72%coin-img-HYPEHYPE+5.22%coin-img-ETHETH+1.01%coin-img-BTCBTC+1.00%coin-img-SOLSOL+1.21%coin-img-USDCUSDC+0.01%coin-img-XRPXRP-0.68%coin-img-TRXTRX-0.54%coin-img-BNBBNB+1.72%coin-img-HYPEHYPE+5.22%
user-avatar
The Manila Times

AsymBio Raises RMB 1.2397 Billion (US$184 Million) in Capital Increase, Asymchem Stake Rises to 83.4965%

AI Market Summary
Asymchem and external investors injected RMB 1.2397bn (US$184m) into biologics CDMO subsidiary AsymBio, lifting Asymchem's stake to 83.4965%. The funding supports capacity expansion and platform investment amid rising demand for outsourced manufacturing of complex biologics (e.g., ADCs, bispecifics). The news is company-specific, signaling improved strategic positioning and capital backing, with limited broader market read-through.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT+2.57%
AI Insight · NCCOGOLD2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Asymchem Group (stock codes: 002821.SZ / 6821.HK) and investors including Hillhouse Qirui injected a total of RMB 1.2397 billion (approximately US$184 million) into its biologics CDMO unit AsymBio, with Asymchem contributing RMB 1.05 billion. Following the capital increase, Asymchem Group’s shareholding in AsymBio will rise to 83.4965%. The move strengthens the group’s capital base and strategic positioning in biologics outsourcing manufacturing, directly benefiting its A-share and Hong Kong-listed entities.
Disclaimer: The content above is only the author's opinion and does not represent BingX’s stance. It shall not be construed as investment advice from BingX. For details, refer to the Terms and Conditions.
Stocks

Risk Warning

Cryptocurrencies and their derivatives are innovative financial products with great volatility and high investment risks.

Although BingX is committed to providing users with easy-to-use trading tools, trading itself is still a highly sophisticated field. Trading digital assets and their derivatives are subject to high market risk and price volatility and may result in partial or total loss of account funds. You must carefully consider and exercise clear judgment to evaluate your financial situation and the aforementioned risks before using BingX Services. You shall be responsible for all losses arising therefrom. If necessary, please consult relevant professionals to make informed decisions before investing. By accessing, downloading, using or clicking on "I agree" to accept any BingX Services provided by BingX, you agree that you have read, understood and accepted all of the terms and conditions stipulated in BingX Terms of Use as well as our Privacy Policy.


Trading by copying or replicating the trades of other traders involves a high level of risks, even when copying or replicating the top-performing traders. Past performance of a BingX community member is not a reliable indicator of his future performance. Content on BingX's trading platform is generated by members of its community and does not contain advice or recommendations by or on behalf of BingX.